⌕
ADMA Biologics · ADMA · Nasdaq
Tenet 72 · Solid
Compare
$13.47−1.54%At closeTenet 72 · Solid
$13.47−0.21 (−1.54%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

ADMA Biologics (ADMA) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~58.4%/yr (FY21→FY25), net margin 28.8%; free cash flow runs at 19% of net income. Check the accrual gap. Worth your attention in FY25: Share count (+75.5%) and Capex step-up ($22.6M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲19.6%
510.2
FY21→FY25CAGR +58.4%/yr
Net income ($M)▼25.7%
146.9
FY21→FY25CAGR —
Free cash flow ($M)▼74.8%
27.8
capex stepped upCAGR —
Diluted EPS▼25.9%
0.60
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+75.5%

139.6mn → 244.9mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$22.6M

▲174% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

Returns vs FCF
115%

$31.9M returned vs $27.8M of FCF in FY25. The gap comes off the balance sheet (see net cash).

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)510.2Revenue−217.4COGS292.8Gross profit−4.8R&D−96.4SG&A191.4Op income−44.5Tax & other146.9Net income

29¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.

Margin trend · direction beats level Gross Operating Net
604530150%sector median net margin ~4%FY21FY25

Over this window: gross 1.4% → 57.4%. Net margin 28.8% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
519.2510.2426.5258.2154.180.9▲19.6%+58.4%
Cost of revenue
163.4217.4206.9169.3118.879.8▲5.1%+28.5%
Gross profit
355.8292.8219.688.935.31.2▲33.3%+297.5%
Research & development
14.54.81.83.33.63.6▲162.7%+6.9%
Selling, general & admin
107.896.478.463.370.355.2▲23.0%+15.0%
Total operating expenses
122.5101.380.667.374.659.5▲25.8%+14.2%
Operating incomefeeds ROC rank
241.2191.4139.021.6−39.4−58.4▲37.7%—
Other income, net
−6.7−8.8−13.3−49.9−26.5−13.3——
Pretax income
234.6182.7125.7−28.2−65.9−71.6▲45.3%—
Income tax
52.135.7−72.00.00.0———
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
182.4146.9197.7−28.2−65.9−71.6▼25.7%—
Per share
Diluted EPSbuyback-sensitive
0.770.600.81−0.13−0.33−0.51▼25.9%—
Diluted shares (mn)
225.82244.90243.34223.98197.87139.58▲0.6%+15.1%
Margins
Gross margin53rd pct in Healthcare
68.5%57.4%51.5%34.4%22.9%1.4%▲5.9pp+55.9pp
Operating margin
46.5%37.5%32.6%8.4%−25.5%−72.1%▲4.9pp+109.6pp
Net margin96th pct in Healthcare
35.1%28.8%46.4%−10.9%−42.8%−88.5%▼17.6pp+117.3pp
† TTM = trailing four quarters through 2026-09-30.
FY11 – FY20 · 10 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 10 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-25 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was ADMA Biologics' revenue last fiscal year?

ADMA Biologics reported revenue of $510.2M in fiscal 2025, up 19.6% from fiscal 2024.

What was ADMA Biologics' net income?

ADMA Biologics reported net income of $146.9M in fiscal 2025, a net margin of 28.8%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.